A woman who was an early adopter of the new weight-loss medication Wegovy shared that it significantly reduced her appetite, sometimes causing her to forget to eat. Sharon Vickers, aged 46, had struggled with weight issues for many years and had gastric sleeve surgery in January 2025, shedding 73lbs before hitting a plateau.
Facing the high cost of GLP-1 injections and a reluctance to self-administer them, Sharon opted to try the newly available Wegovy pill. She purchased a 30-day supply and resumed losing weight.
Having started with a dosage of 1.5mg before increasing to 4mg in April, Sharon found that the pill’s appetite-suppressing effects led her to frequently skip meals. Upon reaching her target weight of 175lbs on May 17, 2026, she gradually tapered off the pills and completely stopped taking them on May 27.
The United States launched the pill in January 2026, followed by the UAE in June, and recently gaining approval from UK authorities. Sharon reported, “It did significantly reduce my appetite, and I was losing about 2lbs a week. By day 10, I realized I was hardly eating and felt full too quickly, which was not my intention.”
Expressing her desire for the pill to aid in managing food urges and portion sizes rather than eradicating hunger entirely, Sharon adopted an alternating regimen, taking the pill every other day until she achieved her desired weight.
Following gastric sleeve surgery in January 2025, Sharon, originally weighing 263lbs, lost 73lbs but struggled to continue losing weight, hovering between 188lbs and 192lbs. She recalled, “I hit a plateau. In September, I looked into GLP-1 injections, but they were prohibitively expensive.”
Sharon highlighted the financial burden of weight loss injections, stating, “The cost was too steep for me. Even the thought of self-injection was daunting. Primarily, the expense deterred me from pursuing them.”
Before commencing the Wegovy pill, Sharon weighed 188lbs and has since slimmed down to 175lbs. Initially starting at 1.5mg, she transitioned to 4mg in April after noticing reduced efficacy with the lower dose.
Reflecting on her journey, Sharon exclaimed, “I feel amazing – like a whole new person. I’ve completed two half marathons, achieving a personal record in my last race by 10 minutes. I am genuinely proud of my progress and accomplishments.”
Having reached her weight goal on May 17, 2026, Sharon initiated the process of gradually discontinuing the pills. Since May 27, she has been pill-free, focusing on maintaining her weight loss.
Sharon emphasized her current focus on weight maintenance without the assistance of GLP-1, acknowledging the challenges of managing cravings and temptations. Despite this, she remains committed to her workout routine and leaves the option open for a potential return to the Wegovy pill if necessary, stating, “Only time will tell.”